Mid-term Patency Rates Research Articles

Mid-term angiographic evaluation of LIMA-LAD anastomoses following LAD endarterectomy in coronary artery bypass grafting

ObjectiveDiffuse coronary artery disease remains a critical issue that heart surgeons continue to research in terms of treatment options. An alternative method applied during coronary bypass surgery to achieve complete revascularization is coronary artery endarterectomy. Since the reliability of this technique and its effects on mortality and morbidity are still debated in the literature. Our objective in conducting this study is to determine the mid-term patency rates in patients who underwent LAD endarterectomy and to explore its future applicability.Materials and MethodsThis study reviewed 20 patients who underwent coronary endarterectomy during CABG in our clinic between January 2014 and December 2021. The data, including contrast imaging to check graft patency, were evaluated retrospectively by reviewing hospital archives and patient files. Patients without LAD endarterectomy were excluded from the study.ResultsLAD endarterectomy and patch-plasty were performed on all patients in the study. In 17 patients, the LIMA graft was anastomosed onto the patch applied to the LAD. It was observed that 12 of the grafts anastomosed to the LAD (60%) were patent during a mean follow-up period of 32.8 ± 25.9 months. The average 4-year survival rate was found to be 95%. Perioperative myocardial infarction occurred in 5 patients (25%). There was no need for high-dose inotropic support, IABP, or ECMO in the postoperative period.ConclusionCoronary artery endarterectomy should be considered a viable option for surgeons to achieve satisfactory revascularization in cases where suitable anastomosis sites on coronary arteries to ensure adequate outflow are not available. Our findings align closely with literature reports indicating that endarterectomy performed on the LAD, with LIMA used as the conduit, leads to promising outcomes.

Comparison of End-To-Side and Side-To-Side Anastomosis Techniques in Arteriovenous Fistula for Hemodialysis: A Systematic Review and Meta-Analysis.

Autogenous arteriovenous fistula (AVF) is the vascular access of choice for chronic kidney disease to patients requiring hemodialysis. However, there still needs to be more consensus on whether the best surgical approach is an end-to-side (ETS) or a side-to-side (STS) anastomosis. This study aims to compare venous maturation rates, midterm patency and postoperative steal syndrome rates between ETS and STS techniques for AVFs. Three databases were searched during November 2022: PubMed, Scopus, and ISI Web of Knowledge. Two independent reviewers examined both titles and abstracts. In all studies, eligibility was assessed, and data regarding the study's characteristics, methods, and considered outcomes were obtained. The odds ratio (OR) assessed maturation rates, 6- and 12-month patency, and steal syndrome. Meta-analysis was done using a fixed effects model if I2 values were under 30%, and a random-effects model from 30-60%. Thirteen studies were included, with a total of 1960 patients studied. Patients undergoing ETS anastomosis had higher maturation rates (OR 3.30 95% confidence interval [CI] 1.81, 6.00, I2=20%). No difference was found in patency at 6months (OR 1.05 95% CI 0.69, 1.59, I2=54%) and 12months (OR 0.75 95% CI 0.46, 1.23, I2=7%). Regarding steal syndrome, STS anastomosis presented a greater risk of developing this postoperative complication (OR 0.24 95% CI 0.11, 0.50, I2=0%). Thepresent review suggests that ETS anastomosis is associated with higher maturation rates and a lower risk of arterial steal syndrome. Randomized clinical trials are required to confirm our findings.

Prosthesis selection for reconstruction of superior vena cava: comparison of midterm patency rates.

This study compared the mid-term patency of expanded polytetrafluoroethylene grafts without rings versus that of bovine pericardial conduits used for superior vena cava reconstruction for various thoracic diseases. Among 80 patients who underwent superior vena cava resection and reconstruction between 2009 and 2023 at our institution, 31 patients who received polytetrafluoroethylene grafts without rings (Polytetrafluoroethylene group) and 28 patients who received bovine pericardial conduits (Bovine group) were enrolled. Median follow-up durations were 19.5 and 64.6 months in the Polytetrafluoroethylene and Bovine groups, respectively. Primary outcome was midterm graft patency rate, and secondary outcomes were early and midterm clinical outcomes, including all-cause mortality and superior vena cava reintervention. Operative mortality was 1.7%. Cumulative incidence of all-cause mortality was not significantly different between the groups. Graft occlusion was detected in 22 patients. Cumulative incidence of graft occlusion was 24.2%, 36.4%, 42.4%, 48.5% and 60.6% at 1 month, 3 months, 6 months, 1 year and 2 years, respectively, in the Bovine group, whereas no graft occlusion was observed in the Polytetrafluoroethylene group (P = 0.007). Although the incidence of graft occlusion was higher in the Bovine group, cumulative incidence of reintervention was not significantly different between the groups (0.0% vs 3.0% in Polytetrafluoroethylene vs Bovine groups at 1 year, P = 0.406). Multivariate analysis demonstrated that bovine pericardial conduit (polytetrafluoroethylene graft as reference) and left brachiocephalic vein reconstruction (right brachiocephalic vein reconstruction as reference) were significant risk factors for graft occlusion. In superior vena cava reconstruction, polytetrafluoroethylene grafts without rings were superior to bovine pericardial conduits in terms of midterm graft patency.

Percutaneous Endovascular Reconstruction of the Common Femoral Artery and Its Bifurcation.

Occlusive lesions of the common femoral artery (CFA) and its bifurcation have traditionally been treated with open surgery. Although long-term patency rates after open surgery are excellent, such repairs are associated with substantial local and general morbidity. In recent years, different treatment options have emerged within percutaneous endovascular repair. We hereby present a narrative review on endovascular treatment modalities and a treatment algorithm for endovascular revascularisation of the CFA and its bifurcation. Lesion analysis, access issues, vessel preparation tools, and types of repairs with or without the involvement of the bifurcation are described. Based on current data, an interventional approach can result in high technical success and acceptable mid-term patency rates. Further comparative evidence with open surgery and/or between the different types of endovascular repairs is required to improve the current treatment algorithm.

Stent Grafts Across the Elbow Joint for Access Salvage.

Covered stent grafts (SGs) are currently being used in a wide variety of situations to maintain function and patency of hemodialysis access circuits. Stent grafts are rarely placed across the elbow joint (EJ), however, due to fear of stent fracture. This study reports on the experience and patency rates with SGs across the EJ. From April 2020 to August 2023, all procedures with SGs placed across the EJ were retrospectively analyzed. A total of 21 patients with SGs placed across the EJ were included in the study. The Covera Vascular Covered Stent (BD, Franklin Lakes, New Jersey, USA) was used in all cases. Of these, 18 were arteriovenous (AV) fistulae, and 3 were AV grafts. Stent grafts were placed for various pathologies, including residual stenosis, perforation, aneurysm, and thrombosis. Follow-up outcomes were obtained from angiographic images on follow-up angiography and included primary patency, primary assisted patency, and secondary patency. The primary patency of the target lesion was 85% (CI=70%-100%) and 85% (CI=70%-100%) at 6 and 12 months, respectively. The primary assisted patency was 85% (CI=70%-100%) and 85% (CI=70%-100%) at 6 and 12 months, respectively. Secondary patency of the access circuit was 95% (CI=86%-100%) at 6 months and 89% (CI=75%-100%) at 12 months. The average follow-up duration was 393 days (range=27-768 days). There were no instances of stent fracture during follow-up. Stent grafts should be placed across the EJ for good short-term and mid-term patency rates. The placement of stent grafts across the elbow joint in hemodialysis patients for access salvage is controversial due to the fear of stent fracture or occlusion. This retrospective study evaluated the placement of stent grafts for access salvage in 21 patients for various etiologies. Good patency rates were seen out to 12 months and no stent fractures were observed. Although longer term data is needed, stent grafts should be considered an acceptable option for access salvage when treating lesions that cross the elbow joint.

Patency and Durability of Stent Grafts Placed in the Dialysis Circuit Cannulation Zone

PurposeTo investigate the safety, durability, and patency rates of stent grafts (SGs) placed in the cannulation zone of hemodialysis access circuits. Materials and MethodsFrom April 2020 to April 2023, all procedures with SGs placed in the cannulation zone were retrospectively analyzed. A total of 40 patients (25 men and 15 women) with SGs placed in the cannulation zone were included in the study. Mean age of the patients was 70 years. The Covera covered stent (BD, Franklin Lakes, New Jersey) was used in all cases. Of these, 26 were arteriovenous (AV) fistulae and 14 were AV grafts. SGs were placed for residual stenosis, perforation, aneurysm, and thrombosis. Follow-up outcomes were determined using follow-up angiographic images and included primary patency, primary-assisted patency, and secondary patency. ResultsThe primary patency of the target lesion was 89% (SD ± 5) and 74% (SD ± 8.4) at 6 and 12 months, respectively. The primary-assisted patency was 89% (SD ± 5.2) and 78% (SD ± 7.6) at 6 and 12 months, respectively. Secondary patency of the access circuit was 97% (SD ± 2.5) at both 6 and 12 months. Mean follow-up was 332 days (range, 28–661 days). All SGs were successfully cannulated for hemodialysis. No cases of stent fracture or stent infection were observed during follow-up. ConclusionsSGs placed for cannulation zone pathologies can be safely cannulated for dialysis and have adequate short- and mid-term patency rates.

Is the Mid-Term Patency Rate of Small-Diameter Viabahn Stent-Grafts in Peripheral Artery Disease Related to Their Length? A Systematic Review.

Small-diameter endografts can be used for the treatment of the peripheral vascular disease, but the patency rate during the follow-up is still under debate. With this review, we aimed at analyzing the mid-term patency of small-diameter Viabahn stent-grafts and investigating the relationship between patency and the length of the graft. We performed a review of articles published until September 2020 and reporting use of ≤7-mm-diameter Viabahn stent-grafts in diseased peripheral arteries. Data on study type, demographic, lesion length, stent-graft diameter, length, and patency (1-year, 3-year, 5-year primary patency, primary-assisted patency, and secondary patency), follow-up, endoleak, and re-intervention rates were extracted and analyzed. A statistical test was applied to identify a correlation between stent-graft length and patency. 16 retrospective and 7 prospective studies reported the outcome of 1613 patients (mean age: 69.6±33.7 years). There was considerable heterogeneity in reporting standards among studies. The diameter of Viabahn stent-grafts ranged 5 to 7mm and the average length was 23.6±12.4cm. Heparin-bonded grafts were used in 46.4% of cases. Mean follow-up time was 26.4±17.6 months. The 1- and 5-year primary patency rate was 75.7% (95% CI, 73.6%-77.8%) and 46.8% (95% CI, 41.0%-52.6%), respectively. The 1- and 5-year primary-assisted patency rate was 80.9% (95% CI, 73.9%-87.8%) and 60.9% (95% CI, 46.4-75.5%), respectively. The 1- and 5-year second-assisted patency was 90.4% (95% CI, 87.4%-93.3%) and 73.7% (95% CI, 64.7%-82.8%), respectively. No correlation between the stent-graft length and patency was found. Small-diameter Viabahn stent-graft implantation represents a safe treatment for patients with peripheral artery disease, and the mid-term patency rate seems not be affected by the length of the graft. The use of small diameter stent-grafts for peripheral vascular disease is an established technique but the patency rate is still under debate. With this review we have investigated the relationship between the mid-term patency and the diameter of the stent-grafts. Afterv having analysed data from 23 published studies including 1613 patients we can conclude that the treatment of the peripheral artery disease with small diameter stent-grafts is safe and the mid-term patency rate seems not be affected by the lenght of the grafts.

Subclavian artery revascularization with subclavian-carotid transposition for TEVAR and non-TEVAR patients.

Subclavian artery revascularization (SAR) has become an increasingly performed technique in patients undergoing thoracic endovascular aortic aneurysm repair (TEVAR), in order to optimize the proximal landing zone, or in patients with significant atherosclerotic diseases. SAR was usually achieved through carotid-subclavian bypass (CSB) which is daunted by graft and patency-related issues, or through subclavian carotid transposition (SCT) which has recently been reconsidered as a potential solution. Nowadays, multiple endovascular strategies including parallel grafts, chimney graft and branch-fenestrated repair, are available in patients unfit for open SAR. However, there is no consensus on the preferable technique in both TEVAR- and non TEVAR-patients. The purpose of this study was to evaluate our experience with SCT in terms of overall postoperative adverse events and mid-term patency rate. We performed a retrospective cohort study, including all patients who underwent SCT between June 2014 and March 2020 at our Division. Preoperative risk factors, symptoms, intraoperative details, postoperative outcomes and follow-up data were collected. A total of 27 patients were included in this study. Indications for SCT included aortic arch debranching for TEVAR for thoracic aortic aneurysm and type B dissection and symptomatic subclavian steal syndrome (SSS). There were no major perioperative adverse events or major neurological complications; five minor adverse events occurred (18.5%) (3 Horner' Syndrome, 1 hematoma requiring reoperation,1 pneumothorax). Peripheral nerve injuries and lymphatic lesions were not recorded. On a mean follow-up of 21±16 months, SCT patency was confirmed in all patients and no deaths occurred. Comparison of baseline and operative characteristics and intraoperative details between groups of patients with or without adverse events did not found differences. SCT should be considered a feasible, effective and safe technique for SAR, with low perioperative complications and optimal mid-term patency. This surgical technique appears to provide a lower risk of neurological events and mortality, particularly in TEVAR patients, reducing the complications caused by the coverage of the left subclavian artery.

Outcomes of Self-Expanding Covered Stents for the Treatment of External ILIAC Artery Obstructive Disease

PurposeTo describe the early results and mid-term patency rates of external iliac artery (EIA) stenting using self-expanding covered stents.MethodsWe conducted a multicenter retrospective study (2015–2021), including patients receiving primary endovascular treatment of external iliac artery occlusive disease with self-expanding covered stents. All patients were treated with the Viabahn (W.L Gore & Associates, Inc., Flagstaff, AZ–USA) stent. Patency and limb salvage rates were estimated with Kaplan–Meier curves.ResultsNinety-three patients (mean age, 69 ± 9 years; 81% males) were treated for disabling claudication in 44%, rest pain in 28%, and tissue loss in 28%. TASC C/D lesions were present in 72% and iliac complete occlusion in 30%. Mean lesion length was 6.9 ± 2.4 cm; 30% had moderate/severe EIA calcifications; and the mean iliac tortuosity index was 1.17 ± 0.13. Technical success was 100%. There was one perioperative death (1.4%) and procedural complication rate was 6.5%. At 42 months (mean, 25 months), primary patency was 89.8% (95%CI 83–98); the presence of EIA tortuosity (tortuosity index > 1.25, 87.7 ± 11% vs 89.9 ± 8%; P = .6) or severe calcifications (87.6 ± 9% vs 96.0 ± 8%; P = .400) had no significant impact. After univariate analysis, the use of a stent with diameter < 8 mm (HR 8.5, 95%CI 3.24–14.22; P < .001) was negatively associated with primary patency.ConclusionsThe use of self-expanding covered stents provided excellent early and mid-term results in the treatment of obstructive disease of the EIA, also in cases of high EIA tortuosity and high grade of calcifications. The use of a < 8 mm-diameter stent was associated with a reduced primary patency.

Outcomes of Endovascular Reconstructive Techniques in Trans-Atlantic Inter-Society Consensus II C-D Aortoiliac Lesions

To describe the outcomes of the endovascular reconstruction of TASC C/D lesions involving the infrarenal aorta and aortic bifurcation with different techniques. This is an observational, retrospective, single-center study. In a 5-year period, we selected all the patients treated with an endovascular procedure for an aorto-iliac TASC C/D lesion involving the infrarenal aorta and/or the aortic bifurcation. Early (<30days) outcomes were mortality, major amputation, and thrombosis. Late mid-term (1 and 3years) outcomes were primary, assisted primary and secondary patency, limb salvage rate, and freedom from reintervention. A total of 87 patients were treated during the index period. Kissing covered stent (cKS), covered reconstruction of aortic bifurcation (CERAB), and unimodular bifurcated AFX Unibody stent-graft (Bif-SG) implantation were performed in 35 (40.4%), 26 (29.8%), and 26 (29.8%) cases, respectively. Bif-SG group included 11 (11/26, 42.3%) patients treated for abdominal aortic aneurysm associated with the obstruction of the aortic bifurcation. Technical success was achieved in all cases and no ruptures or conversions to open surgery were recoded. Median follow-up age was 18months (interquartile range [IQR], 8-34). Overall primary patency rate was 91.2% (95% confidence interval [CI]: 81.3-95.9) at 1year and 83.5% (95% CI: 69.6-91.4) at 3years. Assisted primary patency was 96.9% (95% CI: 87.8-99.2) at 1 and 3years. Secondary patency was 97.8% (95% CI: 85.5-99.6) at 3years. Limb salvage rate was 98.6% (95% CI: 90.1-99.7) at 1 and 3years and, freedom from reintervention was 98.4% (95% CI: 88.9-99.7) at 1year and 87% (95% CI: 66.1-95.4) at 3years. Univariate analysis did not identify any factor affecting primary patency rate. Endovascular reconstruction in severe aorto-iliac obstructions using advanced techniques offered promising mid-term patency rates and profiles of safety. The variety of reconstructive configurations allows surgeons to customize on patients' anatomies the type of revascularization.

Midterm Clinical Outcomes of Retrograde Open Mesenteric Stenting for Mesenteric Ischemia

Retrograde open mesenteric stenting (ROMS) has become a mainstay in treatment of mesenteric ischemia; however, follow-up in contemporary studies is limited. A single-center retrospective review of patients undergoing ROMS from 2007 to 2020 was conducted. Demographics, presentation, and procedural details were reviewed. End points were morbidity and mortality, technical success, primary patency, reinterventions, and freedom from clinical recurrence. ROMS was performed in 34 patients, 19 female (56%). Mean age was 71±10years. Eighteen patients (53%) presented with acute mesenteric ischemia (AMI), 11 (32%) with acute-on-chronic, and 5 (15%) with chronic mesenteric ischemia. Etiology was chronic atherosclerosis with/without in-situ thrombosis in 28 patients (82%), superior mesenteric artery dissection in 3, and 1 each with embolic, vasculitic, and nonocclusive ischemia. Four patients (12%) had prior mesenteric procedures (3 Celiac/1 superior mesenteric artery stent) and 1 had unsuccessful transbrachial stenting attempt. Technical success, defined as successful stenting through a retrograde approach was attained in 31 patients (91%), with the 3 remaining patients treated with transbrachial stenting in 2 and iliomesenteric bypass in 1. Covered stents were used in 21 patients (64%) with or without stent extension with bare-metal stents. Eight patients (23%) required thromboembolectomy and 9 (26%) underwent patch angioplasty. Thirty-day mortality rate was 35%, all in patients with AMI (10) or acute-on-chronic (2). Eighteen patients (53%) underwent bowel resection, all presenting acutely. Early reinterventions within the first 30days were required in 5 patients (15%), including 2 redo ROMS with thrombectomy and endarterectomy, 2 percutaneous stent extensions, and 1 aortic septum fenestration with coiling of a jejunal branch pseudoaneurysm. With a median follow-up of 3.7 (interquartile range: 0.8-5.0) years, in patients surviving discharge, 5 required reintervention yielding freedom from reintervention rates of 87% at 1year and 71% at 3years. All postdischarge reinterventions were endovascular with no conversion to bypass. The overall 1-year and 3-year primary patency rates were 70% and 61% (primary-assisted patency at 1 and 3years was 87% and secondary patency at 1 and 3years was 97%). The freedom from symptom recurrence was 95% at 1 and 3years. ROMS carries high rates of technical success in patients with mesenteric ischemia, despite a high chronic atherosclerotic burden. Although mid-term patency rates are acceptable, AMI is still associated with high early morbidity and mortality, with high rates of associated bowel resection. ROMS is a valuable tool in the armamentarium of vascular surgeons.

Revisiting the Role of Ultrasound Mapping in Arteriovenous Fistula Formation: A Single-Center Experience

Background: The global prevalence of chronic kidney disease (CKD) continues to increase, with the arteriovenous fistula (AVF) as the most preferred vascular access for hemodialysis. Whether routine preoperative ultrasound mapping improves the outcome of AVF formation compared with clinical examination alone remains controversial. Methods: This retrospective study included patients undergoing AVF surgery with and without preoperative ultrasound at our center between September 2017 and August 2020. Outcome measures included AVF early and mid-term outcome. Cox regression analysis was performed to identify independent predictors of favorable AVF outcome. Results: A total of 158 patients received an AVF during the study period. Both groups with (n = 79) and without (n = 79) ultrasound mapping were similar regarding baseline characteristics (age, sex, comorbidities). Patency rates were comparable between the 2 groups at 30 days, 3 months, and 6 months after AVF surgery, although there was a trend toward more favorable outcome for the mapping group ( P = .07). Kaplan-Meier analysis showed that at the end of study, the ultrasound mapping group had a higher mid-term patency rate; however, the improvement was not significant ( P = .07). Cox regression analysis did not reveal age, gender, comorbidities, and ultrasound as predictors of AVF survival. Conclusion: Our study did not find a significant benefit from routine preoperative ultrasound mapping in creating AVFs for hemodialysis. Further well-designed and adequately powered trials are needed to demonstrate the beneficial role of routine preoperative ultrasound mapping for vascular access in CKD coupled with clinical evaluation in short- and long-term AVF outcome.

Midterm Clinical Outcomes Of Retrograde Open Mesenteric Stenting For Mesenteric Ischemia

<h3>INTRODUCTION AND OBJECTIVES</h3> Retrograde open mesenteric stenting (ROMS) has become a mainstay in treatment of mesenteric ischemia, however, follow-up in contemporary studies is limited. <h3>METHODS</h3> Single-center retrospective review of patients undergoing ROMS from 2007-2020 was conducted. Demographics, presentation, procedural details were reviewed. Endpoints were morbidity and mortality, technical success, primary patency, reinterventions, and freedom from clinical recurrence. <h3>RESULTS</h3> ROMS was performed in 34 patients, 19 female (56%). Mean age was 71±10 years. Eighteen patients (53%) presented with acute mesenteric ischemia (AMI), eleven (32%) with acute-on-chronic (ACMI), and five (15%) with chronic mesenteric ischemia (CMI). Etiology was chronic atherosclerosis with/without in-situ thrombosis in 28 patients (82%), SMA dissection in three, and one each with embolic, vasculitic, and non-occlusive ischemia. Four patients (12%) had prior mesenteric procedures (3 Celiac/1 SMA stent) and one had unsuccessful transbrachial stenting attempt. Technical success, defined as successful stenting through retrograde approach was 91%; three remaining patients were treated with transbrachial stenting in two patients and iliomesenteric bypass in one. Covered stents were utilized in 21 patients(64%). Eight patients(23%) required thromboembolectomy and nine(26%) underwent patch angioplasty. Thirty-day mortality rate was 35%, all in patients with AMI (10) or ACMI (2). Eighteen patients (53%) underwent bowel resection, all presenting acutely. Early reinterventions were required in 5 patients (15%); two redo ROMS with thrombectomy and endarterectomy, two percutaneous stent extensions, one aortic septum fenestration. At a median follow-up of 3.7(0.1-8.4) years, cumulative reintervention rate was 24% (8 patients, all four late reinterventions were endovascular with no conversion to bypass), primary patency was 73%(primary-assisted patency 91%, secondary patency 97%), and freedom from clinical recurrence was 95%. <h3>CONCLUSIONS</h3> ROMS carries high rates of technical success in patients with mesenteric ischemia, despite high chronic atherosclerotic burden. While mid-term patency rates are acceptable, early mortality and bowel resection remain common in acute presentations.

Short- and Mid-Term Outcomes of Endovascular Stenting for the Treatment of Post-Thrombotic Syndrome due to Iliofemoral and Caval Occlusive Disease: A Multi-Centric Study from the French Society of Diagnostic and Interventional Cardiovascular Imaging (SFICV).

To assess the results of endovascular treatment in a large population of patients suffering from post-thrombotic syndrome (PTS) due to iliocaval occlusive disease. In this retrospective multi-center study, 698 patients treated by stenting for PTS in 15 French centers were analyzed. Primary, primary assisted, and secondary patency rates were assessed, and clinical efficacy was evaluated using Villalta and Chronic Venous Insufficiency Questionnaire in 20 questions (CIVIQ-20) scores. Outcomes were compared against pre-operative CT-based severity of the post-thrombotic lesions in the thigh (4 grades). Technical success, defined as successful recanalization and stent deployment restoring rapid anterograde flow in the targeted vessel, was obtained in 668 (95.7%) patients with a complication rate of 3.9%. After a mean follow-up of 21.0months, primary patency, primary assisted patency, and secondary patency were achieved in 537 (80.4%), 566 (84.7%), and 616 (92.2%) of the 668 patients, respectively. Venous patency was strongly correlated to the grade of post-thrombotic changes in the thigh, with secondary patency rates of 96.0%, 92.9%, 88.4%, and 78.9%, respectively, for grades 0 to 3 (p = .0008). The mean improvements of Villalta and CIVIQ-20 scores were 7.0 ± 4.7 points (p < .0001) and 19.1 ± 14.8 points (p < .0001), respectively. Endovascular stenting as a treatment option for PTS due to chronic iliocaval venous occlusion generates a high technical success, low morbidity, high midterm patency rate, and clinical improvement. Venous patency was strongly correlated to the severity of post-thrombotic lesions in the thigh.

Current Status and Prospect of Stent Placement for May-Thurner Syndrome.

Stent implantation has been proven to be safe and has become the first-line intervention for May-Thurner syndrome (MTS), with satisfactory mid-term patency rates and clinical outcomes. Recent research has demonstrated that catheter-directed thrombolysis is the preferred strategy when MTS is combined with deep vein thrombosis after self-expanding stent placement. However, the stent used for the venous system was developed based on the experience obtained in the treatment of arterial disease. Consequently, relatively common corresponding complications may come along later, which include stent displacement, deformation, and obstruction. Different measures such as adopting a stent with a larger diameter, improving stent flexibility, and increasing stent strength have been employed in order to prevent these complications. The ideal venous stent is presently being evaluated and will be introduced in detail in this review.

1430 Mid-Term Outcomes After Endovascular Repair of Popliteal Artery Aneurysms Demonstrate Satisfactory Patency Rates and Safety of Stent-Grafts

Abstract Aim Popliteal artery aneurysms (PAAs) are increasingly treated via an endovascular approach. We present mid-term outcomes of popliteal endovascular aneurysm repair (PEVAR) from a single centre. Method A retrospective analysis of a prospective database of consecutive patients who underwent either elective or emergency PEVAR in a single regional vascular centre from January 2010 to August 2020. The patients underwent placement of a heparin-bonded stent-graft (Viabahn Endoprosthesis, WL Gore and Associates, Flagstaff, USA) for PAA &amp;gt;20mm or complications: thromboembolism, rupture or popliteal vein thrombosis. Patency and stent-graft related complications were assessed. Results A total of 64 PAAs (mean size 36.8±13.4mm) were treated in 56 patients (mean age 75±10.7 years, 54 (96%) male). Median follow-up was 29.5 months (IQR 36.75). 30-day mortality was 0%. Technical success rate of stent-graft insertion was 100%. 1-year and 5-year primary patency was 83% and 67% respectively; primary-assisted patency at these time points was 86% and 72%, and the corresponding secondary patency was 89% and 75%. 61 out of 64 treated limbs had &amp;gt;1 vessel runoff. The most frequently occurring complication was stent-graft occlusion which affected 11 (17%) limbs. Stent-graft fracture occurred in 1 patient, resulting in endoleak. Conclusions Viabahn Endoprosthesis can be used successfully in treatment of PAA with acceptable short- and mid-term patency rates. One in five patients in this cohort required a reintervention, with most complications occurring in the first year postoperatively. Stent-graft fracture occurred only in one patient demonstrating that PEVAR is a safe option for PAA management in the intermediate term.

One-year results of stent graft repair for carotid artery pseudo-aneurysm in patients with Behcet's disease.

Behcet's disease is a multisystem disorder of unknown etiology with vascular complications. This study reviewed the mid-term outcome of Behcet's disease patients with carotid artery pseudo-aneurysms treated by endovascular stent-graft repair at our unit. During a period of 11 years, six cases were included. Postoperative ultrasound duplex results were recorded along with computed tomography angiography report done a year after intervention. The mean age (±SD) was 38 (±5.2) years. The mean (±SD) pseudo-aneurysm size was 33 (±12.2) mm. Technical success was 83%; failed cannulation of the internal carotid artery was encountered in one case. On day 2 post-operative, a duplex ultrasound revealed complete exclusion and thrombosis of the false aneurysm in all cases. A year later, a computed tomography angiography revealed a primary patency rate of 80%, and only one case had a recurrent pseudo-aneurysm at the distal margin of the stent graft. All cases, however, had complete thrombosis in the pseudo-aneurysms lumen with a mean (±SD) regression in size of 18 (±6) mm. The mean (±SD) percentage of in-stent stenosis was 34.5% (±11.73%). Stent graft repair for carotid artery pseudo-aneurysm in Behcet's disease patients might be the preferable first line of treatment since it had a high technical success and mid-term primary patency rates, with additional fact that it obviously avoids the hazardous complications of surgery.

Mid-term patency of iliac venous stenting for post-thrombotic syndrome.

Post-thrombotic syndrome (PTS) is the most common chronic complication of deep vein thrombosis. Recent studies suggested that iliac stenting in chronic obstructive venous disease is safe and effective. However, systematic reviews focusing on mid-term efficacy of iliac stenting in post-thrombotic syndrome are lacking. This systematic review aimed to analyze mid-term stent patency rates and clinical outcomes of iliac stenting in post-thrombotic syndrome. Two databases were searched: Pubmed/Medline and Scopus. Articles published between January 2000 and July 2020 were selected and titles and abstracts were independently reviewed. Eighteen articles were included for the qualitative analysis. From this initial set of articles, fourteen articles were included for the quantitative analysis. Overall, 1008 patients were included in this study. The pooled technical success rate was 96%. The pooled primary and secondary patency rates were 98.2% and 100% at 30 days, 78.1% and 94.5% at 12 months and 66.3% and 89.4% at 36 months, respectively. The rates of ulcer healing, pain and edema relief were 78.1%, 53.4% and 48.8%, respectively. The pooled rate of complications including intraoperative venous injury, back pain and stent fracture were 28%, 57.1%, and 5.9%, respectively. Iliac venous stenting in PTS presents durable mid-term patency rates, as well as significant symptomatic improvement. Therefore, endovascular treatment should be considered in symptomatic patients with PTS.

Patency of Hemashield grafts versus ringed Gore-Tex grafts in middle hepatic vein reconstruction for living donor liver transplantation.

Backgrounds/AimsOwing to the short supply of homologous vein allografts, we previously used ringed Gore-Tex vascular grafts for middle hepatic vein (MHV) reconstruction in living donor liver transplantation. When ringed Gore-Tex grafts became unavailable, we used Hemashield vascular grafts. This study aimed to compare the patency and complication rates of Hemashield and ringed Gore-Tex grafts.MethodsThis retrospective two-arm study compared the study group that received Hemashield grafts (n=157) and the propensity score-matched control group that received ringed Gore-Tex grafts (n=157).ResultsIn the Hemashield and Gore-Tex groups, the recipient age was 54.7±9.4 and 53.3±6.3 years; Model for End-stage Liver Disease scores were 15.9±9.2 and 16.9±8.3; and graft-recipient weight ratios were 1.07±0.24 and 1.10±0.23, respectively. In the Hemashield group, V5 reconstruction was performed using single (n=113, 72.0%), double (n=39, 24.8%), and triple (n=3, 1.9%) anastomoses. The proportion of double and triple anastomoses for V5 and V8 was higher in the Hemashield group than in the Gore-Tex group. Two (1.3%) patients required MHV conduit stenting owing to early thrombosis of the Hemashield graft. There was no difference in conduit occlusion- free patient survival rates between groups (p=0.91). The incidence of accidental conduit migration in the Hemashield and Gore-Tex groups was 0 (0%) and 2 (1.3%), respectively.ConclusionsHemashield grafts used in MHV reconstruction demonstrated acceptably high short- and mid-term patency rates, no incidences of conduit migration, easy handling, and good flexibility for length adjustment. Therefore, we suggest that the Hemashield graft is the preferentially suitable prosthetic material for MHV reconstruction.

Fenestrated versus debranching thoracic endovascular aortic repair for endovascular treatment of distal aortic arch and descending aortic lesions

BackgroundCervical debranching, followed by thoracic endovascular aortic repair (TEVAR), is well-established for treating aortic arch lesions. However, total endovascular repair with fenestrated endografts has not been adequately studied. Thus, we performed a comparison of the two techniques. MethodsThe present study was a single-center, retrospective study comparing the treatment of thoracic aortic lesions with custom-made fenestrated stent-grafts (fenestrated TEVAR [fTEVAR]) with a single fenestration for the left subclavian artery (LSA), a scallop for the left carotid artery, and hybrid repair with a thoracic stent-graft and cervical debranching of the LSA. Emergency cases were excluded. ResultsFrom 2012 to 2018, 19 patients (58% male) underwent elective fTEVAR (group A) and 17 patients (82% male) underwent debranching TEVAR (dTEVAR; group B). The mean age ± standard deviation in group A was 65.8 ± 2 years and 68 ± 3 years in group B. Left carotid–subclavian bypass was performed in 15 of 17 patients (88%) and transposition of the LSA in 2 of 17 patients (12%) in group B. The two groups were comparable regarding comorbidities, except for peripheral arterial disease: 5 of 19 patients in group A (26%) and none in group B had had peripheral arterial disease (P = .049). Dissection or post-dissection aneurysm was the indication for treatment in 6 of 19 patients in the fTEVAR group (group A) and in 12 of 17 patients in the dTEVAR group (group B; 31.6% vs 70.6%; P = .04). The indication for the remaining patients was a degenerative aortic aneurysm. Technical success was achieved in all cases, except for one case of dTEVAR owing to a type Ia endoleak. The mean endovascular operative time was 191 ± 120 minutes for fTEVAR and 130 ± 75 minutes for dTEVAR (P = NS). The mean operative time for the debranching procedure was 181 ± 97 minutes. No deaths or major strokes had occurred in the early postoperative period (30 days). Of the 17 patients in group B, 5 (29.4%) had experienced a local complication related to the debranching procedure. The mean follow-up was 14.6 ± 2 months for group A and 17 ± 2 months for group B. Of the 19 patients in group A and 17 patients in group B, 2 (10.5%) and 6 (35.3%) had required an unplanned reintervention related to the thoracic stent-graft during the follow-up period, respectively (P = NS). The estimated freedom from unplanned reintervention at 12 months was 86% for group A and 81% for group B. Primary patency of the LSA stent-graft or the carotid–subclavian bypass/transposition was 100% in both groups. ConclusionsBoth techniques showed excellent midterm patency rates for the target vessel and high technical success rate. The operation times were shorter for the fTEVAR group and complications related to the debranching procedure were avoided.